NDAC
This article was originally published in The Tan Sheet
Executive Summary
Meeting tentatively scheduled for April 22-23, according to Jan. 3 Federal Register notice listing FDA advisory committee dates in 2002. NDAC, which last met in May 2001 to consider switching second-generation antihistamines, may be asked to revisit OTC suitability of cholesterol-lowering statin drugs; in July 2000, committee voted against switching Pravachol (Bristol-Myers Squibb), Mevacor (Merck). FDA's TSE committee is slated to meet Jan. 16-17, June 26-27, Oct. 17-18; Food Advisory Committee is scheduled to meet June 4-5, Sept. 24-25...
You may also be interested in...
Acetaminophen Toxicity Headed To NDAC, New FDA Drug Safety Group
Potential liver toxicity risks from acetaminophen use are likely to be among the topics at the inaugural meeting of FDA's Drug Safety & Risk Management Subcommittee
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.